Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types.

The Journal of molecular diagnostics : JMD - 1 Dec 2021

Elliott Andrew, Zhang Jian, Zhang Qing, Swensen Jeffrey, Martin Daniel, Xiu Joanne, Geynisman Daniel M, Vaena Daniel, Herzog Thomas J, Holloway Robert W, El-Deiry Wafik S, Spetzler David, Heath Elisabeth, Stafford Phillip, Korn W Michael

Abstract excerpt

CDK12 biallelic inactivation is associated with a distinct genomic signature of focal tandem duplications (FTDs). Gene fusions resulting from FTDs increase neoantigen load, raising interest in CDK12 as a biomarker of response to immune checkpoint inhibitors. Despite evidence of FTDs in multiple CDK12-altered cancer types, notably prostate and ovarian, report of fusion-associated neoantigen load is limited to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cyclin-Dependent Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epitopes

Share to Gene Fusion

Share to HLA Antigens

Share to Loss of Function Mutation

Share to Neoplasms

Share to Tumor Microenvironment

Source

Identifiers

PMID: 34562615
DOI: 10.1016/j.jmoldx.2021.08.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types.PMID 34562615Read ↗

Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator PhenotypeSemantic proximity Read ↗

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.Semantic proximity Read ↗

Harnessing gene fusion-derived neoantigens for 'cold' breast and prostate tumor immunotherapy.Semantic proximity Read ↗

Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer.Semantic proximity Read ↗

Mutational Analysis of Gene Fusions Predicts Novel MHC Class I–Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate CancerSemantic proximity Read ↗

INTEGRATE-neo: a pipeline for personalized gene fusion neoantigen discoverySemantic proximity Read ↗

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Semantic proximity Read ↗

Detailed Molecular and Immune Marker Profiling of Archival Prostate Cancer Samples Reveals an Inverse Association between TMPRSS2:ERG Fusion Status and Immune Cell Infiltration.Semantic proximity Read ↗

Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.Semantic proximity Read ↗

Characterizing CDK12-Mutated Prostate CancersSemantic proximity Read ↗

A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype.Semantic proximity Read ↗

A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotypeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.